Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

610 related articles for article (PubMed ID: 37536040)

  • 1. Synchronous targeted delivery of TGF-β siRNA to stromal and tumor cells elicits robust antitumor immunity against triple-negative breast cancer by comprehensively remodeling the tumor microenvironment.
    Yang M; Qin C; Tao L; Cheng G; Li J; Lv F; Yang N; Xing Z; Chu X; Han X; Huo M; Yin L
    Biomaterials; 2023 Oct; 301():122253. PubMed ID: 37536040
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The programmed site-specific delivery of LY3200882 and PD-L1 siRNA boosts immunotherapy for triple-negative breast cancer by remodeling tumor microenvironment.
    Zhang P; Qin C; Liu N; Zhou X; Chu X; Lv F; Gu Y; Yin L; Liu J; Zhou J; Huo M
    Biomaterials; 2022 May; 284():121518. PubMed ID: 35462305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Codelivery of Shikonin and siTGF-β for enhanced triple negative breast cancer chemo-immunotherapy.
    Li J; Zhao M; Liang W; Wu S; Wang Z; Wang D
    J Control Release; 2022 Feb; 342():308-320. PubMed ID: 35031387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer.
    Yi M; Wu Y; Niu M; Zhu S; Zhang J; Yan Y; Zhou P; Dai Z; Wu K
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36460337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-Delivery Nanomicelles for Potentiating TNBC Immunotherapy by Synergetically Reshaping CAFs-Mediated Tumor Stroma and Reprogramming Immunosuppressive Microenvironment.
    Zhang Y; Han X; Wang K; Liu D; Ding X; Hu Z; Wang J
    Int J Nanomedicine; 2023; 18():4329-4346. PubMed ID: 37545872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TGF-β inhibition combined with cytotoxic nanomedicine normalizes triple negative breast cancer microenvironment towards anti-tumor immunity.
    Panagi M; Voutouri C; Mpekris F; Papageorgis P; Martin MR; Martin JD; Demetriou P; Pierides C; Polydorou C; Stylianou A; Louca M; Koumas L; Costeas P; Kataoka K; Cabral H; Stylianopoulos T
    Theranostics; 2020; 10(4):1910-1922. PubMed ID: 32042344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Colocalized targeting of TGF-β and PD-L1 by bintrafusp alfa elicits distinct antitumor responses.
    Lan Y; Yeung TL; Huang H; Wegener AA; Saha S; Toister-Achituv M; Jenkins MH; Chiu LY; Lazorchak A; Tarcic O; Wang H; Qi J; Locke G; Kalimi D; Qin G; Marelli B; Yu H; Gross AW; Derner MG; Soloviev M; Botte M; Sircar A; Ma H; Sood VD; Zhang D; Jiang F; Lo KM
    J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35858707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer.
    Camorani S; Passariello M; Agnello L; Esposito S; Collina F; Cantile M; Di Bonito M; Ulasov IV; Fedele M; Zannetti A; De Lorenzo C; Cerchia L
    J Exp Clin Cancer Res; 2020 Sep; 39(1):180. PubMed ID: 32892748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer.
    Takai K; Le A; Weaver VM; Werb Z
    Oncotarget; 2016 Dec; 7(50):82889-82901. PubMed ID: 27756881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TGF-β blockade-improved chemo-immunotherapy with pH/ROS cascade-responsive micelle via tumor microenvironment remodeling.
    Dai L; Li X; Zheng X; Fu Z; Yao M; Meng S; Zhang J; Han B; Gao Q; Chang J; Cai K; Yang H
    Biomaterials; 2021 Sep; 276():121010. PubMed ID: 34247042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances.
    Lind H; Gameiro SR; Jochems C; Donahue RN; Strauss J; Gulley JL; Palena C; Schlom J
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32079617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy.
    Niu M; Yi M; Wu Y; Lyu L; He Q; Yang R; Zeng L; Shi J; Zhang J; Zhou P; Zhang T; Mei Q; Chu Q; Wu K
    J Hematol Oncol; 2023 Aug; 16(1):94. PubMed ID: 37573354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1.
    Yi M; Zhang J; Li A; Niu M; Yan Y; Jiao Y; Luo S; Zhou P; Wu K
    J Hematol Oncol; 2021 Feb; 14(1):27. PubMed ID: 33593403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
    Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
    J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relaxin-encapsulated polymeric metformin nanoparticles remodel tumor immune microenvironment by reducing CAFs for efficient triple-negative breast cancer immunotherapy.
    Zhang H; Chen L; Zhao Y; Luo N; Shi J; Xu S; Ma L; Wang M; Gu M; Mu C; Xiong Y
    Asian J Pharm Sci; 2023 Mar; 18(2):100796. PubMed ID: 37008735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual inhibition of TGF-β and PD-L1: a novel approach to cancer treatment.
    Gulley JL; Schlom J; Barcellos-Hoff MH; Wang XJ; Seoane J; Audhuy F; Lan Y; Dussault I; Moustakas A
    Mol Oncol; 2022 Jun; 16(11):2117-2134. PubMed ID: 34854206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanoparticle-integrated dissolving microneedles for the co-delivery of R848/aPD-1 to synergistically reverse the immunosuppressive microenvironment of triple-negative breast cancer.
    Huang S; Wen T; Wang J; Wei H; Xiao Z; Li B; Shuai X
    Acta Biomater; 2024 Mar; 176():344-355. PubMed ID: 38244662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulating the immunosuppressive tumor microenvironment to enhance breast cancer immunotherapy using pH-responsive hybrid membrane-coated nanoparticles.
    Gong C; Yu X; Zhang W; Han L; Wang R; Wang Y; Gao S; Yuan Y
    J Nanobiotechnology; 2021 Feb; 19(1):58. PubMed ID: 33632231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer stem cells in immunoregulation and bypassing anti-checkpoint therapy.
    Rouzbahani E; Majidpoor J; Najafi S; Mortezaee K
    Biomed Pharmacother; 2022 Dec; 156():113906. PubMed ID: 36306594
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multifunctional nanodrug performs sonodynamic therapy and inhibits TGF-β to boost immune response against colorectal cancer and liver metastasis.
    Huang S; Ding D; Lan T; He G; Ren J; Liang R; Zhong H; Chen G; Lu X; Shuai X; Wei B
    Acta Biomater; 2023 Jul; 164():538-552. PubMed ID: 37037269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.